This story was delivered to Business Insider Intelligence “Digital Health Briefing” subscribers hours before appearing on Business Insider. To be the first to know, please click here.
In order to advance innovation and keep pace with the rapidly evolving healthcare industry, the US Food and Drug Administration (FDA) is modernizing the approval process most medical device manufacturers undergo when bringing new products to market.
D esigner therapies are treatments tailored to a specific disease, and nowhere is the need greater for new therapies than in a group of nervous system disorders, known as “neurodegenerative diseases.”
Many of these diseases are common and well-known, such as Alzheimer’s or Parkinson’s disease. However, some are very rare, genetic disorders that are the consequence of a defective gene. In all these diseases, a mutant protein that misfolds causes the degeneration and death of neurons. One effective therapeutic strategy is to prevent the rogue protein from ever being made.
Spinocerebellar ataxia type 7 (SCA7) is one such disease in which nerves in different parts of the brain, including the eye, degenerate, which leads to blindness and difficulty walking, speaking, and balancing. SCA7 is dominantly inherited — which means that you just need one bad copy of the mutation to cause disease. The disease occurs when a short section of DNA that encodes ataxin-7 gene is erroneously repeated — like a word in a book printed two or three times. In this case, three chemical units of the DNA sequence — C-A-G — are repeated over and over.
New research suggests that exposure to childhood adversity is associated with reduced cognitive control and alterations in key brain networks. The findings, which appear in the journal Social Cognitive and Affective Neuroscience, could help explain the link between childhood adversity and depression.
“My work focuses on how we can use objective biomarkers to aid in clinical decision making,” said study author Scott A. Langenecker of the University of Utah.
“One challenging clinical decision point is what to do when individuals have recovered from a depressive episode. Do we continue treatment? Do we exercise regular check-ins? Or do we just wait and see?”
The hepatitis B virus (HBV), which spreads through blood and bodily fluids and invades liver cells, is thought to kill just under 1 million people every year around the world, mostly from cancer or scarring (cirrhosis) of the liver. HBV is less likely to be fatal than HIV, and many people who carry the virus don’t have symptoms. But because more than 250 million people live with chronic HBV infections, more than 7 times the number with HIV, its global death toll now rivals that of the more-feared virus.
Viral hepatitis is on the rise. Tackling hepatitis B in Africa is key to fighting back. Viral hepatitis is on the rise. Tackling hepatitis B in Africa is key to fighting back.
Optical fibers are then inserted through an area called the perineum, found between the testes and the anus, and directly into the prostate gland. Afterwards, the scientists turn on a red laser that is induced through the optical fibers. This process utilizes the photosensitivity of the WST11 drug and activates it. Upon activation, free radicals are released within the area, attacking and destroying the tumors. Unlike conventional treatments which might affect a general area of body cells, this treatment is localized. The nearby cells are left more or less unharmed.
Beating The Big ‘C’
The trial for this prostate cancer treatment has shown promising results. Endgadget reports that, from the 415 participating men, nearly half were rid of the malignant disease by the end of treatment. This is a huge improvement compared to conventional procedures, which only have an average success rate of about 14 percent. Of those that had cancer in remission, only six percent needed to have their affected prostate removed, which is again a stark contrast to the conventional procedures’ 30 percent.
Project for Awesome (P4A) 2018 is finally here, and you can help us to win much-needed funds at no cost to you by voting for the videos supporting our charity.
Every year, a number of charities are chosen through voting, and they each receive a sum of money based on what the fundraiser at P4A has raised. In the past, charities have received around $25,000 each, which is a considerable sum, especially for a small non-profit org such as LEAF.
With these funds, we can purchase new equipment to support reporting at conferences and events and to bring our audience the best media experience possible. We are also planning to host a second conference in New York City in 2019, and this will be far more ambitious in scale and will be a two-day event rather than the single-day conference we held this year; with your support, we can make this one of the top conferences supporting the field of rejuvenation biotechnology and make high-quality footage available to the public. Finally, we can use the funds to hire new writers in order to bring you even more high-quality news articles and educational pieces about aging and research.
